Ranolazine terminates atrial flutter and fibrillation in a canine model

Ashish A. Bhimani, Tomoo Yasuda, Shervin A. Sadrpour, Celeen M. Khrestian, Seungyup Lee, Dewan Zeng, Luiz Belardinelli, Albert L. Waldo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background Ranolazine has been shown to have antiarrhythmic properties. Objective We tested the hypothesis that intravenous ranolazine would terminate induced atrial flutter (AFL) or atrial fibrillation (AF) in the canine sterile pericarditis model. Methods In 6 dogs with sterile pericarditis, we performed electrophysiological measurements of the atrial effective refractory period (AERP) and conduction time (CT) while pacing from the right atrial appendage, Bachmann bundle, and the posteroinferior left atrium at cycle lengths (CLs) of 400, 300, and 200 ms before and after the administration of ranolazine. In 13 induced episodes of AFL (n = 9) and AF (n = 4), ranolazine was administered intravenously as a 3.2 mg/kg bolus, followed by a maintenance infusion of 0.17 mg/(kg·min). Six episodes (4 AFL and 2 AF) were induced in the open-chest state to perform simultaneous, multisite (486 electrodes), epicardial mapping of the arrhythmia and its termination. Results Ranolazine terminated 7 of 9 AFL and 3 of 4 AF episodes. Ranolazine significantly prolonged the AFL CL by a mean of 43 ms (P

Original languageEnglish (US)
Pages (from-to)1592-1599
Number of pages8
JournalHeart Rhythm
Volume11
Issue number9
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Atrial Flutter
Atrial Fibrillation
Canidae
Pericarditis
Epicardial Mapping
Atrial Appendage
Heart Atria
Ranolazine
Cardiac Arrhythmias
Electrodes
Thorax
Maintenance
Dogs

Keywords

  • Atrial fibrillation
  • Atrial flutter
  • Mapping
  • Ranolazine
  • Termination

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Bhimani, A. A., Yasuda, T., Sadrpour, S. A., Khrestian, C. M., Lee, S., Zeng, D., ... Waldo, A. L. (2014). Ranolazine terminates atrial flutter and fibrillation in a canine model. Heart Rhythm, 11(9), 1592-1599. https://doi.org/10.1016/j.hrthm.2014.05.038

Ranolazine terminates atrial flutter and fibrillation in a canine model. / Bhimani, Ashish A.; Yasuda, Tomoo; Sadrpour, Shervin A.; Khrestian, Celeen M.; Lee, Seungyup; Zeng, Dewan; Belardinelli, Luiz; Waldo, Albert L.

In: Heart Rhythm, Vol. 11, No. 9, 2014, p. 1592-1599.

Research output: Contribution to journalArticle

Bhimani, AA, Yasuda, T, Sadrpour, SA, Khrestian, CM, Lee, S, Zeng, D, Belardinelli, L & Waldo, AL 2014, 'Ranolazine terminates atrial flutter and fibrillation in a canine model', Heart Rhythm, vol. 11, no. 9, pp. 1592-1599. https://doi.org/10.1016/j.hrthm.2014.05.038
Bhimani AA, Yasuda T, Sadrpour SA, Khrestian CM, Lee S, Zeng D et al. Ranolazine terminates atrial flutter and fibrillation in a canine model. Heart Rhythm. 2014;11(9):1592-1599. https://doi.org/10.1016/j.hrthm.2014.05.038
Bhimani, Ashish A. ; Yasuda, Tomoo ; Sadrpour, Shervin A. ; Khrestian, Celeen M. ; Lee, Seungyup ; Zeng, Dewan ; Belardinelli, Luiz ; Waldo, Albert L. / Ranolazine terminates atrial flutter and fibrillation in a canine model. In: Heart Rhythm. 2014 ; Vol. 11, No. 9. pp. 1592-1599.
@article{62f0d4ec003641f2ab0a1b1843597783,
title = "Ranolazine terminates atrial flutter and fibrillation in a canine model",
abstract = "Background Ranolazine has been shown to have antiarrhythmic properties. Objective We tested the hypothesis that intravenous ranolazine would terminate induced atrial flutter (AFL) or atrial fibrillation (AF) in the canine sterile pericarditis model. Methods In 6 dogs with sterile pericarditis, we performed electrophysiological measurements of the atrial effective refractory period (AERP) and conduction time (CT) while pacing from the right atrial appendage, Bachmann bundle, and the posteroinferior left atrium at cycle lengths (CLs) of 400, 300, and 200 ms before and after the administration of ranolazine. In 13 induced episodes of AFL (n = 9) and AF (n = 4), ranolazine was administered intravenously as a 3.2 mg/kg bolus, followed by a maintenance infusion of 0.17 mg/(kg·min). Six episodes (4 AFL and 2 AF) were induced in the open-chest state to perform simultaneous, multisite (486 electrodes), epicardial mapping of the arrhythmia and its termination. Results Ranolazine terminated 7 of 9 AFL and 3 of 4 AF episodes. Ranolazine significantly prolonged the AFL CL by a mean of 43 ms (P",
keywords = "Atrial fibrillation, Atrial flutter, Mapping, Ranolazine, Termination",
author = "Bhimani, {Ashish A.} and Tomoo Yasuda and Sadrpour, {Shervin A.} and Khrestian, {Celeen M.} and Seungyup Lee and Dewan Zeng and Luiz Belardinelli and Waldo, {Albert L.}",
year = "2014",
doi = "10.1016/j.hrthm.2014.05.038",
language = "English (US)",
volume = "11",
pages = "1592--1599",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Ranolazine terminates atrial flutter and fibrillation in a canine model

AU - Bhimani, Ashish A.

AU - Yasuda, Tomoo

AU - Sadrpour, Shervin A.

AU - Khrestian, Celeen M.

AU - Lee, Seungyup

AU - Zeng, Dewan

AU - Belardinelli, Luiz

AU - Waldo, Albert L.

PY - 2014

Y1 - 2014

N2 - Background Ranolazine has been shown to have antiarrhythmic properties. Objective We tested the hypothesis that intravenous ranolazine would terminate induced atrial flutter (AFL) or atrial fibrillation (AF) in the canine sterile pericarditis model. Methods In 6 dogs with sterile pericarditis, we performed electrophysiological measurements of the atrial effective refractory period (AERP) and conduction time (CT) while pacing from the right atrial appendage, Bachmann bundle, and the posteroinferior left atrium at cycle lengths (CLs) of 400, 300, and 200 ms before and after the administration of ranolazine. In 13 induced episodes of AFL (n = 9) and AF (n = 4), ranolazine was administered intravenously as a 3.2 mg/kg bolus, followed by a maintenance infusion of 0.17 mg/(kg·min). Six episodes (4 AFL and 2 AF) were induced in the open-chest state to perform simultaneous, multisite (486 electrodes), epicardial mapping of the arrhythmia and its termination. Results Ranolazine terminated 7 of 9 AFL and 3 of 4 AF episodes. Ranolazine significantly prolonged the AFL CL by a mean of 43 ms (P

AB - Background Ranolazine has been shown to have antiarrhythmic properties. Objective We tested the hypothesis that intravenous ranolazine would terminate induced atrial flutter (AFL) or atrial fibrillation (AF) in the canine sterile pericarditis model. Methods In 6 dogs with sterile pericarditis, we performed electrophysiological measurements of the atrial effective refractory period (AERP) and conduction time (CT) while pacing from the right atrial appendage, Bachmann bundle, and the posteroinferior left atrium at cycle lengths (CLs) of 400, 300, and 200 ms before and after the administration of ranolazine. In 13 induced episodes of AFL (n = 9) and AF (n = 4), ranolazine was administered intravenously as a 3.2 mg/kg bolus, followed by a maintenance infusion of 0.17 mg/(kg·min). Six episodes (4 AFL and 2 AF) were induced in the open-chest state to perform simultaneous, multisite (486 electrodes), epicardial mapping of the arrhythmia and its termination. Results Ranolazine terminated 7 of 9 AFL and 3 of 4 AF episodes. Ranolazine significantly prolonged the AFL CL by a mean of 43 ms (P

KW - Atrial fibrillation

KW - Atrial flutter

KW - Mapping

KW - Ranolazine

KW - Termination

UR - http://www.scopus.com/inward/record.url?scp=84906935371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906935371&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2014.05.038

DO - 10.1016/j.hrthm.2014.05.038

M3 - Article

C2 - 25066042

AN - SCOPUS:84906935371

VL - 11

SP - 1592

EP - 1599

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 9

ER -